Prodotti competitors / Area Onco-Ema 27 gennaio 2023 Pembrolizumab (Keytruda) gains FDA Approval for patients in stage IB-IIIA of lung cancer (NSCLC), regardless of PD-L1 expression
Prodotti competitors / Area Onco-Ema 22 dicembre 2022 Carrick Therapeutics and Menarini announce Clinical Trial collaboration to evaluate Samuraciclib and Elacestrant combination against HR+, HER2- breast cancer
Prodotti competitors / Area Onco-Ema 17 dicembre 2022 Oncology: CHMP meeting highlights Dicembre 2022
Prodotti competitors / Area Onco-Ema, Area Kite 5 dicembre 2022 CHMP Minutes for September 2022 - Oncology
Prodotti competitors / Area Onco-Ema 21 novembre 2022 Evorpacept (CD47 blocker) in sviluppo clinico in diverse indicazioni oncologiche (UC, AML, MDS, HNSCC, GC)
Prodotti competitors / Area Kite, Area Onco-Ema 14 novembre 2022 Meeting highlights from the CHMP: Oncology - 7-10 November 2022
Prodotti competitors / Area HIV 7 novembre 2022 CytoDyn Announces Voluntary Withdrawal of its application for leronlimab in HIV-MDR due to CRO Data Management Issues
Prodotti competitors / Area Onco-Ema, Area Kite 24 ottobre 2022 CHMP meeting highlights of 10-13 October 2022 - Oncology
Prodotti competitors / Area Onco-Ema, Area Kite 19 settembre 2022 Meeting highlights from CHMP 12-15 September 2022 - Oncology
Prodotti competitors / Area Onco-Ema 2 settembre 2022 FDA Grants Accelerated Approval to Trastuzumab Deruxtecan (Enhertu) for HER2-mutated NSCLC and approved companion diagnostics for selection of patients
